FGF18 and osteoarthritis: FGF18 has emerged as an important therapeutic target in osteoarthritis, with recombinant human FGF18 (sprifermin) showing promising results in clinical trials for primary OA (Hochberg et al., 2019; Eckstein et al., 2021).